4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2nd Generation Chimeric Antigen Receptor-Modified T Cells

4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2nd Generation Chimeric Antigen Receptor-Modified T Cells

While chimeric antigen receptor-modified T (CAR-T) cells have shown great success for the treatment of B cell leukemia, their efficacy appears to be compromised in B cell derived lymphoma and solid tumors. Optimization of the CAR design to improve persistence and cytotoxicity is a focus of the curre...

Full description

Bibliographic Details
Main Authors: Qiang Dai, Ping Han, Xinyue Qi, Fanlin Li, Min Li, Lilv Fan, Huihui Zhang, Xiaoqing Zhang, Xuanming Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-11-01
Series:Frontiers in Immunology
Subjects:
4-1BB
chimeric antigen receptor-modified T
lymphoma
immunotherapy
CD20
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2020.539654/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2020.539654/full

Similar Items